Antibody Discovery Platform

Our proprietary Single Plasma Cell Interrogation (SPIN® ) platform uses microfluidic technology to isolate antigen-specific plasma cells and single cell technology to analyze native paired antibody genes. Automation-facilitated high-throughput screening has made the interrogation of the natural antibody repertoire possible.

Antibody Platform Technology

Benefits of the SPIN® Platform include:

  1. A Wide Selection of Species: Because of the diverse nature of the SPIN® Platform, any immunized animals or vaccinated humans can be analyzed for monoclonal antibody development.
  2. High Affinity: Antibody genes amplified from terminal differentiated plasma cells with native pairs of HC and LC ensure high affinity of antibodies.
  3. Broad Diversity: There is no bias during the process of single plasma cell isolation and functional selection.
  4. Short Timeline: The advances of SPIN® technology shortens the monoclonal antibody development timeline from 4 months to 4 weeks.